At the news
? BEARISHIMPACT 6/10 PRESS-RELEASE filed May 11, 2026 at 16:05 ET
Sana Biotechnology reported Q1 2026 GAAP net loss of $0.17 per share, slightly better than the $0.21 loss in Q1 2025 but worse than the $0.15 consensus estimate. The company highlighted progress toward clinical trials for SC451 (type 1 diabetes) and SG293 (non-Hodgkin lymphoma), a strategic collaboration with Mayo Clinic including a $25M equity investment, and a cash runway into 2027. The EPS miss and lack of revenue are bearish, but the pipeline progress and collaboration provide some offset.
- GAAP net loss per share of $0.17 vs consensus estimate of $0.15 (miss of 13.3%)
- Net loss of $47.2M in Q1 2026 vs $49.4M in Q1 2025
- Cash, cash equivalents, and marketable securities of $101.1M as of March 31, 2026, down from $138.4M at year-end 2025
- Non-GAAP operating cash burn of $37.0M in Q1 2026 vs $46.6M in Q1 2025
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access